Successful Pregnancy following Busulfan and Cyclophosphamide Conditioning and Allogeneic Bone Marrow Transplantation for Chronic Myeloid Leukemia  by Matias, Kleber et al.
LETTER TO THE EDITOR
Biology of Blood and Marrow Transplantation 14:944-945 (2008)
Q 2008 American Society for Blood and Marrow Transplantation
1083-8791/08/1408-0001$32.00/0Successful Pregnancy
following Busulfan and
Cyclophosphamide
Conditioning and
Allogeneic Bone Marrow
Transplantation for
Chronic Myeloid Leukemia
Recovery of gonadal function in patients after allo-
geneic stem cell transplantation for hematologic ma-
lignancies is uncommon, and only a few cases have
been reported. We report the case of a 39-year-old
woman who had a normal full-term delivery 8 years
after allogeneic bone marrow transplantation for
chronic myeloid leukemia. Conditioning consisted of
cyclophosphamide 120 mg/kg over 2 days and Busul-
fan 16 mg/kg over 4 days (BuCy). To our knowledge,
this is the second reported case of pregnancy after
BuCy conditioning.
An increasing number of young women suffering
from leukemia and other malignant and nonmalignant
disorders are being cured by stem cell transplantation
(SCT), raising the concern of late adverse effects of
this procedure. These young people often wish to re-
sume a high quality of life, and usually wish to have
children. Most pretransplant conditioning protocols
include alkylating agents, irradiation, or both, either
of which can cause germinal epithelium depletion
and infertility [1]. In the nontransplant setting, the fre-
quency of early menopause, azoospermia and germ cell
destruction varies with the type and total dose of alky-
lating agent or irradiation, as well as patient sex and
age at the time of treatment administration [2,3]. De-
spite the gonadal toxicity of SCT, the literature docu-
ments successful pregnancies after therapy; however,
the true incidence of pregnancy and pregnancy-related
complications after transplantationare unknown [4-11].
We report a successful pregnancy and delivery after
allogeneic bone marrow transplantation for chronic
myeloid leukemia (CML) conditioned with busulfan
and cyclophosphamide.
A 31-year-old woman was diagnosed with Phila-
delphia positive CML in the chronic phase in April
1998 after routine admission blood cell count. Clin-
ical examination was normal, without splenomegaly.944Hematologic values were: hemoglobin 10.9 g/dL,
white blood cells: 105  109/L (8% promyelocytes,
15% myelocytes, 15% metamyelocytes, 50% band
cells, and 3% segmented cells), platelets: 1128 109/L.
Bone marrow examination was hypercellular without
excess of blasts. Karyotype showed 46, XX, t(9;22)
with no other abnormalities. Cytoreduction with
hydroxyurea was started followed by Interferon-alpha-
2b 5,000,000 UI 5 times per week from May 1998 to
December 1999, achieving hematologic remission. Al-
logeneic bone marrow transplantation from her HLA
identical sister was performed in July 2000 after con-
ditioning with busulfan 16 mg/kg over 4 days and
cyclophosphamide 120 mg/kg over 2 days (BuCy).
Anti-GVHD prophylaxis included methotrexate and
cyclosporine A. She presented acute grade I skin
and chronic grade I liver GVHD. In 2006, during fol-
low-up with no evidence of disease, she was found to
be pregnant, and in October 2006 she gave birth to
a term, normal-weight healthy boy. She was at that
time 39 years old. There were no complications during
pregnancy and no evidence of recurrence of CML after
delivery.
Recovery of gonadal function in patients after SCT
for hematologic malignancies is uncommon, and only
a few cases have been reported. In allogeneic SCT, re-
covery of ovarian function ranges from 14% to 24%,
and the major factors that influence posttransplant fer-
tility are total body irradiation (TBI) and age [12,13].
Sanders et al. [8] described from a population of
1522 transplant survivors 146 pregnancies in 76 allo-
graft patients conditioned with cyclophosphamide
with or without busulfan or TBI. Of 73 women treated
with BuCy only 1 recovered ovarian function, but she
did not become pregnant after SCT. They also found
that partners of male patients had uncomplicated preg-
nancies and normal children, whereas female recipi-
ents of allografts had a high incidence of miscarriage,
premature labor, and low birthweight babies. How-
ever, the infants were apparently not at risk for
increased incidence of congenital anomalies.
Salooja et al. [11] assessed the outcome of concep-
tion in women and partners of men relating to 19,412
allogeneic and 17,950 autologous transplant patients.
232 (0.6%) conceived after SCT. Seventy-four were
women after allo-SCT, including only 1 patient re-
ceiving BuCy as conditioning regimen (described
separately in a case report [7]). Rates of congenital
anomalies, developmental delay, and malignant dis-
ease were not higher than normal in the offspring
of SCT patients. Three CML patients relapsed after
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a theoretic disturbance of the graft-versus-leukemia ef-
fect as a consequence of pregnancy [11,14].
To our knowledge, this is the second reported case
of successful pregnancy after BuCy conditioning and
allogeneic bone marrow transplantation in a female
patient and the first reported case of pregnancy after
SCT and BuCy in CML receiving chemotherapy be-
fore transplant (hydroxyurea). The first reported case
was in a thalassemia patient [7].
The effect of BuCy on fertility remains unclear,
and deserves further study and continued follow-
up evaluation with pregnancy outcome on transplant
recipients to determine the actual incidence of fertility,
pregnancy-related complications, leukemia relapse, as
well as mutational injury that could affect their
offspring.
The erratic gastrointestinal absorption of busulfan
as a result of oral administration may lead to intra- and
interindividual variability, bioavailability, and pharma-
cokinetics [15,16], and the impact of intravenous ad-
ministration or different dosing schedules (eg, once
daily) in fertility needs further investigation.
In vitro fertilization (IVF) with embryo cryopres-
ervation constitutes a valid alternative for young
women cured after SCTwith some successful reported
cases in the literature [17,18]. On the other hand, cryo-
preservation of mature oocytes following IVF/intracy-
toplasmic sperm injection offers some advantages, but
it is still limited by its low success rate. Emerging and
exciting techniques of germ cell/gonadal tissue cryo-
preservation (banking) followed by autotransplanta-
tion have been clinically explored but it should be
considered experimental in humans for the present
time until greater evidence regarding efficacy and
safety is accrued [19].
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